Journal Watch · Nature Communications · 2026

Evolutionary tuning of a biosynthetic gene cluster drives furanocoumarin accumulation and diversification.

These findings elucidate how BGC architecture, gene copy number and functional innovation collectively drive phytochemical innovation, providing a blueprint for engineering medicinal FC biosynthesis.

Han X, Guo M, Yang P et al.Nature Communications3 min readPharma relevance 40/100

DOI: 10.1038/s41467-026-74337-wPMID: 42304001Study type: research study

TL;DR

These findings elucidate how BGC architecture, gene copy number and functional innovation collectively drive phytochemical innovation, providing a blueprint for engineering medicinal FC biosynthesis.

Key findings

  • The ancestral Angelica s.l. clade retains an FC BGC configuration with OMTs on separate chromosomes and PTs performing only C-prenylation.
  • In contrast, Angelica s.s. evolves an FC BGC, where core enzymes and OMTs co-localise on the same chromosome, with C2'H copy number expansion correlating with elevated expression and PTs enabling both C- and O-prenylation, collectively enhancing FC production and structural diversity.
  • These findings elucidate how BGC architecture, gene copy number and functional innovation collectively drive phytochemical innovation, providing a blueprint for engineering medicinal FC biosynthesis.

What they did

Here, we conduct comparative genomics between high-FC Angelica sensu stricto (s.s.) and low-FC Angelica sensu lato (s.l.) species. We reveal an FC biosynthetic gene cluster (BGC) comprising core enzymes (p-coumaroyl-CoA 2'-hydroxylases (C2'Hs), prenyltransferases (PTs)) and peripheral O-methyltransferases (OMTs).

Full abstract (original)

Background: Deciphering evolutionary drivers of biosynthetic pathways could enhance bioactive compound production. In Angelica, interspecific variation in furanocoumarins (FCs) accumulation reflects divergent pathway evolution.

What they did: Here, we conduct comparative genomics between high-FC Angelica sensu stricto (s.s.) and low-FC Angelica sensu lato (s.l.) species. We reveal an FC biosynthetic gene cluster (BGC) comprising core enzymes (p-coumaroyl-CoA 2'-hydroxylases (C2'Hs), prenyltransferases (PTs)) and peripheral O-methyltransferases (OMTs).

Results & conclusions: The ancestral Angelica s.l. clade retains an FC BGC configuration with OMTs on separate chromosomes and PTs performing only C-prenylation. In contrast, Angelica s.s. evolves an FC BGC, where core enzymes and OMTs co-localise on the same chromosome, with C2'H copy number expansion correlating with elevated expression and PTs enabling both C- and O-prenylation, collectively enhancing FC production and structural diversity. These findings elucidate how BGC architecture, gene copy number and functional innovation collectively drive phytochemical innovation, providing a blueprint for engineering medicinal FC biosynthesis.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-74337-w · PubMed 42304001.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking Nature Communications for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Communications study find?

These findings elucidate how BGC architecture, gene copy number and functional innovation collectively drive phytochemical innovation, providing a blueprint for engineering medicinal FC biosynthesis.

What type of study is this?

It is a research study, published in Nature Communications in 2026. Here, we conduct comparative genomics between high-FC Angelica sensu stricto (s.s.) and low-FC Angelica sensu lato (s.l.) species.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-74337-w. PubMed ID: 42304001. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Han X, Guo M, Yang P et al.. Evolutionary tuning of a biosynthetic gene cluster drives furanocoumarin accumulation and diversification.. Nature Communications (2026). DOI: 10.1038/s41467-026-74337-w.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/evolutionary-tuning-of-a-biosynthetic-gene-cluster-drives-furanocoumarin-74337w/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides